Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC)

Table 3 Association of the level of promoter methylation with clinicopathologic charactristics of NSCLC

Genes	Gender (n = 96)			Histologic type (n = 96)			Smoking history (n = 96)
	Female	Male	P	SCC	ADC	P	Y	N	P
	(n = 30)	(n = 66)		(n = 66)	(n = 30)		(n = 66)	(n = 30)
CALCA	145.0 ± 149.6	112.1 ± 106.5	0.28	152.1 ± 152.1	96.4 ± 90.6	0.07	155.2 ± 150.2	89.6 ± 92.7	0.03*
*CDH1*	33.1 ± 18.7	31.5 ± 21.2	0.71	35.4 ± 19.2	26.3 ± 18.6	0.03*	32.2 ± 18.7	33.4 ± 21.3	0.77
*DAPK1*	18.5 ± 59.6	23 ± 45.2	0.71	26.2 ± 65.8	5.9 ± 7.6	0.09	17.4 ± 59.6	25.4 ± 45.2	0.52
*IRX2*	96.4 ± 131.5	63.9 ± 34.8	0.19	92.3 ± 115.7	72.9 ± 103.6	0.43	95.3 ± 132.1	66.3 ± 36.1	0.24
*TIMP3*	60.5 ± 72.8	50.9 ± 39.1	0.50	64.9 ± 71.7	41.3 ± 39.8	0.09	61.5 ± 72.8	48.8 ± 38.9	0.37
*PAX6*	23.4 ± 15.1	24.2 ± 13.8	0.78	24.0 ± 15.5	23.1 ± 12.8	0.79	23.9 ± 15.6	23.3 ± 12.6	0.85
Genes	Lymph node metastasis (n = 96)			Pleural indentation (n = 96)			Invasion or Adhesion (n = 96)
	Y	N	P	Y	N	P	Y	N	P
	(n = 26)	(n = 70)		(n = 21)	(n = 75)		(n = 31)	(n = 65)
*CALCA*	175.7 ± 175.1	119.5 ± 119.1	0.08	129.9 ± 132.5	136 ± 140.2	0.86	174.5 ± 160	115.1 ± 122.5	0.048*
*CDH1*	31.0 ± 13.9	33.1 ± 21.2	0.64	35.3 ± 21.2	31.8 ± 18.9	0.47	30.7 ± 16.6	33.5 ± 20.7	0.52
*DAPK1*	40.3 ± 100.5	12.3 ± 18.5	0.03*	12.4 ± 11.9	21.9 ± 62.3	0.49	10.9 ± 10.6	24.2 ± 66.6	0.27
*IRX2*	42.7 ± 51	91.2 ± 127.2	0.47	73.1 ± 38.4	89.9 ± 124.9	0.54	71.8 ± 48.3	93.1 ± 131.6	0.38
*TIMP3*	69.3 ± 91	53.2 ± 51	0.28	53.9 ± 42.9	58.6 ± 69.2	0.77	52.7 ± 53.1	59.8 ± 69.1	0.61
*PAX6*	23.2 ± 14.2	23.9 ± 14.9	0.83	25.2 ± 13.9	23.3 ± 14.9	0.59	25.8 ± 15.7	22.7 ± 14.1	0.32

ISSN: 1746-1596